Table 7. Univariate analysis of various clinical factors on survivals of locally advanced nasopharyngeal carcinoma (n = 553).
| Number | 5y LRFS | p value | 5y RRFS | p value | 5y DMFS | p value | 5y DFS | p value | 5y OS | p value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | |||||||||||
| ≤ 48 | 274 | 84.6% | 0.060 | 92.7% | 0.913 | 77.9% | 0.236 | 67.1% | 0.221 | 83.1% | 0.040* |
| > 48 | 279 | 90.1% | 92.0% | 81.3% | 69.9% | 76.4% | |||||
| Gender | |||||||||||
| male | 409 | 85.5% | 0.039* | 92.6% | 0.855 | 76.1% | 0.006* | 65.2% | 0.005* | 77.5% | 0.152 |
| female | 144 | 93.1% | 91.6% | 89.5% | 78.0% | 86.4% | |||||
| T category | |||||||||||
| T1–3 | 434 | 88.7% | 0.266 | 91.3% | 0.083 | 82.0% | 0.030* | 71.0% | 0.071 | 80.8% | 0.591 |
| T4 | 119 | 83.2% | 96.4% | 70.7% | 59.7% | 76.5% | |||||
| N category | |||||||||||
| N0–1 | 194 | 85.7% | 0.631 | 96.6% | 0.015* | 82.9% | 0.149 | 71.8% | 0.164 | 83.7% | 0.212 |
| N2–3 | 359 | 88.4% | 90.1% | 77.9% | 66.8% | 77.7% | |||||
| Stage | |||||||||||
| III | 331 | 88.0% | 0.531 | 92.6% | 0.155 | 83.5% | 0.011* | 72.5% | 0.032* | 82.2% | 0.174 |
| IV | 222 | 86.6% | 87.0% | 73.3% | 62.3% | 75.9% | |||||
| Chemotherapy | |||||||||||
| yes | 527 | 87.0% | 0.053 | 96.2% | 0.711 | 80.0% | 0.044* | 68.4% | 0.568 | 80.7% | 0.002* |
| no | 26 | 100% | 92.2% | 69.8% | 69.8% | 60.5% | |||||
| Concurrent chemotherapy | |||||||||||
| yes | 278 | 87.3% | 0.258 | 92.7% | 0.823 | 83.6% | 0.050 | 71.6% | 0.266 | 82.6% | 0.082 |
| no | 275 | 87.4% | 92.1% | 75.7% | 65.4% | 77.0% | |||||
| Induction chemotherapy | |||||||||||
| yes | 493 | 87.5% | 0.855 | 93.0% | 0.160 | 79.9% | 0.207 | 69.0% | 0.466 | 80.7% | 0.057 |
| no | 60 | 86.4% | 87.8% | 76.1% | 63.9% | 71.4% | |||||
| Adjuvant chemotherapy | |||||||||||
| yes | 202 | 87.6% | 0.569 | 92.2% | 0.865 | 78.0% | 0.846 | 65.4% | 0.764 | 83.5% | 0.208 |
| no | 351 | 87.5% | 92.5% | 80.5% | 70.3% | 77.4% | |||||
| Chemotherapy Strategy | |||||||||||
| Induction CT. + RT. | 59 | 83.4% | 0.509 | 87.8% | 0.137 | 73.9% | 0.395 | 63.6% | 0.624 | 62.6% | 0.030* |
| Induction CT. + CCRT. | 244 | 88.8% | 93.6% | 84.0% | 73.5% | 83.0% | |||||
| Induction CT. + Adjuvant CT. | 190 | 86.9% | 93.6% | 76.8% | 65.3% | 83.1% | |||||
| CCRT. +/–Adjuvant CT. | 34 | 78.0% | 82.8% | 81.2% | 60.2% | 80.0% | |||||
| Induction chemotherapy regimens | |||||||||||
| TPF/TP/GP | 409 | 87.7% | 0.686 | 92.8% | 0.999 | 81.6% | 0.140 | 69.8% | 0.539 | 83.3% | 0.058 |
| PF | 79 | 85.8% | 93.6% | 72.2% | 65.8% | 72.2% | |||||
| Adjuvant chemotherapy regimens | |||||||||||
| TPF/TP/GP | 149 | 88.2% | 0.944 | 92.2% | 0.774 | 77.0% | 0.469 | 66.0% | 0.325 | 84.7% | 0.577 |
| PF | 56 | 84.9% | 90.9% | 82.5% | 65.3% | 80.9% | |||||
| Total dose of cisplatin | |||||||||||
| ≥ 300 mg/m2 | 338 | 86.4% | 0.377 | 93.2% | 0.506 | 82.0% | 0.016* | 70.0% | 0.218 | 84.2% | 0.005* |
| < 300 mg/m2 | 215 | 89.3% | 90.8% | 75.5% | 66.0% | 72.3% | |||||
| Radiation boost | |||||||||||
| yes | 74 | 73.7% | 0.004* | 83.1% | 0.000* | 71.2% | 0.085 | 52.2% | 0.004* | 80.2% | 0.995 |
| no | 479 | 89.5% | 93.8% | 80.9% | 71.1% | 79.5% | |||||
| Radiation interruption > 3 days | |||||||||||
| yes | 46 | 92.8% | 0.609 | 92.7% | 0.777 | 82.7% | 0.675 | 73.3% | 0.780 | 69.4% | 0.592 |
| no | 507 | 87.0% | 92.4% | 79.3% | 68.1% | 80.4% |
Abbreviation: CT. = chemotherapy; CCRT. = concurrent chemotherapy; RT. = radiation.
*
indicated p < 0.05.